database / metabolic

Linaclotide

also known as Linzess

approved metabolic gastrointestinal modified — mass check n/a

101 heavy atoms · 185 bonds · drag to pan, scroll to zoom C59O21N15S6

Skeletal structure drawn from the computed atomic coordinates in PubChem CID 16158208. Carbons are implicit vertices; hydrogens on carbon are suppressed, as in any structural formula. Nothing here is estimated — every atom sits where PubChem placed it.

Research reference only. The observations below are recorded in the cited literature. Nothing here is advice or a recommendation, and no dosing information is published on this site.

Sequence

CCEYCCNPACTGCY

Cys-Cys-Glu-Tyr-Cys-Cys-Asn-Pro-Ala-Cys-Thr-Gly-Cys-Tyr

hydrophobic
positive
negative
polar
aromatic
glycine
proline
cysteine

Modified molecule. Three disulfide bonds lock the peptide into its active fold.

Backbone carries modifications, so computed backbone mass is not comparable to the reported mass of the complete molecule.

Molecular data

Chemical fields come from the PubChem compound record; computed values are derived from the sequence shown above.
molecular formula	C59H79N15O21S6
molecular weight	1526.8 Da (PubChem)
computed backbone mass	1532.77 Da
length	14 residues
net charge (pH 7.4)	-1
mean hydropathy	0.32
half-life	not characterised
delivery route	oral
PubChem CID	16158208
PDB	not characterised
UniProt parent	not characterised

Mechanism

Guanylate cyclase-C agonist acting locally in the intestinal lumen.

Reported targets: GC-C

Experimental structure

No experimental structure of this peptide is deposited in the PDB. Nothing is rendered here — a predicted fold would not be a structure, and this site does not draw one.

Reported effects

Each row is an outcome described in the literature indexed for this peptide. Reported in the cited work — not a claim, not a recommendation.

Reported observations and the corpus they are drawn from.
reported outcome	where it appears
intestinal fluid secretion	Efficacy safety of linaclotide combined with polyethylene glycol for bowel p… Frontiers in gastroenterology (Lausanne, Switzerland) 2026
IBS-C outcomes in trials	Identification and Quantification of Structurally Related Peptide Impurity i… Rapid communications in mass spectrometry : RCM 2026

Registered trials

Records from ClinicalTrials.gov. Listed for reference — this project sponsors no trial and is not involved in any of them.
NCT	title	status	phase
NCT07569419	Proof of Principle Study for an Efficacy Trial of Linaclotide for Cystic Fibrosis	RECRUITING	EARLY_PHASE1
NCT02837783	A Study of the Effect of Linaclotide on Abdominal Girth in Participants With Irritable Bowel	TERMINATED	PHASE4
NCT04026113	Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irrita	COMPLETED	PHASE3
NCT03119584	Efficacy of Linaclotide in Type II Diabetics With Chronic Constipation	ACTIVE_NOT_RECRUITING	PHASE4
NCT02220348	A Lactation Study in Women Who Are Breastfeeding or Pumping and Are Receiving Linaclotide Th	COMPLETED	PHASE1

Literature (8)

Efficacy safety of linaclotide combined with polyethylene glycol for bowel preparation in patients with constipation: a meta-analysis — Frontiers in gastroenterology (Lausanne, Switzerland) 2026